111.48 - 114.40
76.75 - 114.39
5.09M / 4.21M (Avg.)
23.96 | 4.77
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 10Y revenue/share CAGR while JHX stands at 57.06%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-100.00%
Negative 5Y CAGR while JHX stands at 44.00%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-100.00%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 10Y net income/share CAGR while JHX is at 1387.57%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-100.00%
Negative 5Y net income/share CAGR while JHX is 395.92%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-100.00%
Negative 3Y CAGR while JHX is 244.27%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-100.00%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-100.00%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-100.00%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.